FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hyam Levitsky

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Disorders

Physiology

Co-author Network

Publications

TOP 3
Cedrik Michael Britten; L H Butterfield; G Ferrari; Cécile Gouttefangeas; A Hoos; C Huber; Sylvia Janetzki; Michael Kalos; Hyam I Levitsky; Holden T Maecker; C J M Melief; J O'Donnell-Tormey; Kunle Odunsi; L J Old; T H M Ottenhoff; C Ottensmeier; G Pawelec; M Roederer; B O Roep; P Romero; Sjoerd H van der burg; S Walter; M M Davis
T cell assays and MIATA: the essential minimum for maximum impact.
Gang Zhou; Hyam I Levitsky
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.
Douglas E Gladstone; Carol Ann Huff; Richard J Jones; Yvette L Kasamon; Hyam I Levitsky; Leo Luznik; William Matsui; Jonathan D Powell; Richard F Ambinder; F. JAVIER BOLANOS MEADE; Ivan Borrello; Robert A Brodsky; Ian W Flinn; Ephraim J Fuchs; Marianna Zahurak; Lode J Swinnen
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hyam Levitsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Cedrik Michael Britten; L H Butterfield; G Ferrari; Cécile Gouttefangeas; A Hoos; C Huber; Sylvia Janetzki; Michael Kalos; Hyam I Levitsky; Holden T Maecker; C J M Melief; J O'Donnell-Tormey; Kunle Odunsi; L J Old; T H M Ottenhoff; C Ottensmeier; G Pawelec; M Roederer; B O Roep; P Romero; Sjoerd H van der burg; S Walter; M M Davis
T cell assays and MIATA: the essential minimum for maximum impact.
Immunity 2012;37(1):1-2.
2012: Gang Zhou; Hyam I Levitsky
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.
Clinical & developmental immunology 2012;2012():124187.
2011: Douglas E Gladstone; Carol Ann Huff; Richard J Jones; Yvette L Kasamon; Hyam I Levitsky; Leo Luznik; William Matsui; Jonathan D Powell; Richard F Ambinder; F. JAVIER BOLANOS MEADE; Ivan Borrello; Robert A Brodsky; Ian W Flinn; Ephraim J Fuchs; Marianna Zahurak; Lode J Swinnen
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.
Leukemia & lymphoma 2011;52(11):2076-81.
2011: Christopher Hourigan; Hyam I Levitsky
Evaluation of current cancer immunotherapy: hemato-oncology.
Cancer journal (Sudbury, Mass.) 2011;17(5):309-24.
2011: Gang Zhou; Zhi-Chun Ding; Jie Fu; Hyam I Levitsky
Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(4):2148-55.
2011: Christopher G Kanakry; Allan Hess; Christopher D Gocke; Christopher J Thoburn; FERDYNAND KOS; Christian Meyer; Janet Briel; Leo Luznik; B Douglas Smith; Hyam I Levitsky; Judith E Karp
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Blood 2011;117(2):608-17.
2011: Bernard A Fox; Thomas F Gajewski; Jerome Galon; Jared A Gollob; Cécile Gouttefangeas; Fabio Grizzi; Michele Guida; Leif Håkansson; Kristen Hege; Ronald B Herberman; F Stephen Hodi; Axel Hoos; Christoph Huber; Patrick Hwu; Kohzoh Imai; Elizabeth M Jaffee; Sylvia Janetzki; Carl H June; Pawel Kalinski; Howard L Kaufman; Koji Kawakami; Yutaka Kawakami; Ulrich Keilholtz; Samir N Khleif; Rolf Kiessling; Beatrix Kotlan; Guido Kroemer; Rejean Lapointe; Hyam I Levitsky; Michael T Lotze; Cristina Maccalli; Michele Maio; Francesco M Marincola; Jens-Peter Marschner; Michael J Mastrangelo; Giuseppe Masucci; Ignacio Melero; Cornelius Melief; William Murphy; Brad Nelson; Andrea Nicolini; Michael I Nishimura; Jill O'Donnell-Tormey; Kunle Odunsi; Pamela S Ohashi; Lloyd J Old; Christian Ottensmeier; Michael Papamichail; Giorgio Parmiani; Graham Pawelec; Enrico Proietti; Shukui Qin; Robert Rees; Antoni Ribas; Ruggero Ridolfi; Gerd Ritter; Licia Rivoltini; Pedro J Romero; Mohamed L Salem; Dolores J Schendel; Rik J Scheper; Barbara Seliger; Padmanee Sharma; Hiroshi Shiku; Harpreet Singh-Jasuja; Wenru Song; Per Thor Straten; Hideaki Tahara; Zhigang Tian; Sjoerd H van der burg; Paul von Hoegen; Ena Wang; Marij Jp Welters; JON WIGGINTON; Hauke Winter; Tara Withington; Jedd D Wolchok; Weihua Xiao; Laurence Zitvogel; Heinz Zwierzina; Steinar Aamdal; James P Allison; Paolo Antonio Ascierto; Michael B Atkins; Jirina Bartunkova; Lothar Bergmann; Neil Berinstein; Cristina C Bonorino; Ernest Borden; Jonathan L Bramson; Cedrik M Britten; Lisa H Butterfield; Xuetao Cao; William E Carson; Alfred E Chang; Dainius Characiejus; A Raja Choudhury; George Coukos; Tanja de Gruijl; Robert O Dillman; Harry Dolstra; Glenn Dranoff; Lindy G Durrant; James H Finke; Mary L Disis
Defining the critical hurdles in cancer immunotherapy.
Journal of translational medicine 2011;9(1):214.
2011: Jonathan Michael Gerber; LU QIN; Jeanne Kowalski; B Douglas Smith; Constance A Griffin; Milada S Vala; Michael I Collector; Brandy Perkins; Marianna Zahurak; William Matsui; Christopher D Gocke; Saul J Sharkis; Hyam I Levitsky; Richard J Jones
Characterization of chronic myeloid leukemia stem cells.
American journal of hematology 2011;86(1):31-7.
2011: Cedrik Michael Britten; S Janetzki; Sjoerd H van der burg; Christoph Huber; M Kalos; Hyam I Levitsky; Holden T Maecker; C J M Melief; J O'Donnell-Tormey; K Odunsi; L J Old; Graham Pawelec; B O Roep; P Romero; A Hoos; M M Davis
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
Cancer immunology, immunotherapy : CII 2011;60(1):15-22.
2010: Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert A Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette L Kasamon; Steven Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
Blood 2010;115(16):3224-30.
2010: B Douglas Smith; Yvette L Kasamon; Jeanne Kowalski; Christopher D Gocke; KATHLEEN MURPHY; Carole B Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; LU QIN; Christina Chia; Barbara A Biedrzycki; Thomas C Harding; Guang Haun Tu; Richard J Jones; Kristen Hege; Hyam I Levitsky
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(1):338-47.
2009: Sylvia Janetzki; Cedrik Michael Britten; Michael Kalos; Hyam I Levitsky; Holden T Maecker; Cornelius J M Melief; Lloyd J Old; Pedro Romero; Axel Hoos; Mark M Davis
"MIATA"-minimal information about T cell assays.
Immunity 2009;31(4):527-8.
2009: Ivan Borrello; Hyam I Levitsky; Wendy Stock; Dorie Sher; LU QIN; Daniel J DeAngelo; Edwin P Alyea; Richard M Stone; Lloyd E Damon; Charles A Linker; Daniel J Maslyar; Kristen M Hege
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
Blood 2009;114(9):1736-45.
2009: Osnat B Kashtan; Sebastien Morisot; Richard Hildreth; CORY BRAYTON; Hyam I Levitsky; Curt I Civin
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(1):696-705.
2009: Christopher Long; Hanneke W M van Laarhoven; Jeff W M Bulte; Hyam I Levitsky
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.
Cancer research 2009;69(7):3180-7.
2008: Brian A Rabinovich; Yang Ye; Tamara Etto; Jie Qing Chen; Hyam I Levitsky; Willem W Overwijk; Laurence J N Cooper; Juri G Gelovani; Patrick Hwu
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(38):14342-6.
2008: HEATHER SYMONS; MOSHE LEVY; Jie Wang; Xiaotao Zhou; Gang Zhou; Sarah E Cohen; Leo Luznik; Hyam I Levitsky; Ephraim J Fuchs
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(5):499-509.
2008: Justin Stebbing; Christopher Wood; Michael Atkins; Ronald Bukowski; Stephen Litwin; mark bower; Andrew Parsa; Hyam I Levitsky
Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
Cancer 2008;112(5):955-61.
2008: Paria Mirmonsef; Gladys Tan; Gang Zhou; Tricia Morino; Kimberly Noonan; Ivan Borrello; Hyam I Levitsky
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
Blood 2008;111(4):2112-21.
2007: Lothar Finke; Kerry Wentworth; Brent Blumenstein; Natalie S Rudolph; Hyam I Levitsky; Axel Hoos
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
Vaccine 2007;25 Suppl 2():B97-B109.
2007: Gang Zhou; Hyam I Levitsky
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(4):2155-62.
2007: Chien-Fu Hung; Ya-Chea Tsai; Liangmei He; G Coukos; I Fodor; LU QIN; Hyam I Levitsky; Tzyy-choou Wu
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
Gene therapy 2007;14(1):20-9.
2006: Piotr Walczak; Jesus Ruiz-Cabello; Dorota A Kedziorek; Assaf A Gilad; Sopo Lin; Brad Barnett; LU QIN; Hyam I Levitsky; Jeff W M Bulte
Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent.
Nanomedicine : nanotechnology, biology, and medicine 2006;2(2):89-94.
2006: Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam I Levitsky; Eduardo M Sotomayor
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
Blood 2006;107(7):2871-8.
2006: Gang Zhou; Charles G Drake; Hyam I Levitsky
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
Blood 2006;107(2):628-36.
2005: Kimberly Noonan; William Matsui; paolo serafini; Rebecca Carbley; Gladys Tan; Jahan Khalili; Mark Bonyhadi; Hyam I Levitsky; Katharine A Whartenby; Ivan Borrello
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
Cancer research 2005;65(5):2026-34.
2004: Gang Zhou; Zhengbin Lu; John D McCadden; Hyam I Levitsky; Aimee L Marson
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
The Journal of experimental medicine 2004;200(12):1581-92.
2004: Ching-Tai Huang; Creg J Workman; Dallas B Flies; Xiaoyu Pan; Aimee L Marson; Gang Zhou; Edward L Hipkiss; TANNA RAVI; Jeanne Kowalski; Hyam I Levitsky; Jonathan D Powell; Drew M Pardoll; Charles G Drake; Dario A A Vignali
Role of LAG-3 in regulatory T cells.
Immunity 2004;21(4):503-13.
2003: Alex Cuenca; Fengdong Cheng; Hongwei Wang; Jason Brayer; Pedro Horna; Lingping Gu; Harold Bien; Ivan Borrello; Hyam I Levitsky; Eduardo M Sotomayor
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cancer research 2003;63(24):9007-15.
2003: Yan Cui; Erin Kelleher; Erin Straley; Ephraim J Fuchs; Kevin Gorski; Hyam I Levitsky; Ivan Borrello; Curt I Civin; Stephen P Schoenberger; Linzhao Cheng; Drew M Pardoll; Katharine A Whartenby
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Nature medicine 2003;9(7):952-8.
2003: Leo Luznik; Jill E Slansky; Sanju Jalla; Ivan Borrello; Hyam I Levitsky; Drew M Pardoll; Ephraim J Fuchs
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
Blood 2003;101(4):1645-52.
2002: Franck Housseau; Daniel A Langer; Samuel D Oberholtzer; Anitha Moorthy; Hyam I Levitsky; Drew M Pardoll; Suzanne Topalian
Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines.
International journal of cancer. Journal international du cancer 2002;98(1):57-62.
2001: Eduardo M Sotomayor; Ivan Borrello; FM Rattis; Alex Cuenca; J Abrams; K Staveley-O'Carroll; Hyam I Levitsky
Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
Blood 2001;98(4):1070-7.
2001: bo wu; JM Wu; Alexei Miagkov; Robert N Adams; Hyam I Levitsky; Daniel B Drachman
Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(7):4773-9.
2001: Hyam I Levitsky
When magic bullets miss their mark.
Blood 2001;97(4):833.
2000: Ivan Borrello; Eduardo M Sotomayor; FM Rattis; S K Cooke; L Gu; Hyam I Levitsky
Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
Blood 2000;95(10):3011-9.
2000: Hyam I Levitsky
Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 3():S281-90.
2000: Z Lu; L Yuan; X Zhou; Eduardo M Sotomayor; Hyam I Levitsky; Drew M Pardoll
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.
The Journal of experimental medicine 2000;191(3):541-50.
2000: William G Nelson; Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Kim; CE Weber; AA Baccala; M A Goeman; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S67-72.
1999: Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Lim; CE Weber; AA Baccala; M A Goemann; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall; William G Nelson
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Cancer research 1999;59(20):5160-8.
1999: Eduardo M Sotomayor; Ivan Borrello; E Tubb; J P Allison; Hyam I Levitsky
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11476-81.
1999: Ivan Borrello; Eduardo M Sotomayor; S Cooke; Hyam I Levitsky
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
Human gene therapy 1999;10(12):1983-91.
1999: Eduardo M Sotomayor; Ivan Borrello; E Tubb; FM Rattis; H Bien; Z Lu; S Fein; Stephen P Schoenberger; Hyam I Levitsky
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
Nature medicine 1999;5(7):780-7.
1999: L C Hwang; S Fein; Hyam I Levitsky; William G Nelson
Prostate cancer vaccines: current status.
Seminars in oncology 1999;26(2):192-201.
1998: K Hung; R Hayashi; Anne Lafond-Walker; Charles J Lowenstein; Drew M Pardoll; Hyam I Levitsky
The central role of CD4(+) T cells in the antitumor immune response.
The Journal of experimental medicine 1998;188(12):2357-68.
1998: Karen S Lindeman; Carol A Hirshman; J S Kuhl; Hyam I Levitsky; Charles W Emala
Chronic oxytocin pretreatment inhibits adenylyl cyclase activity in cultured rat myometrial cells.
Biology of reproduction 1998;59(5):1108-15.
1998: K Staveley-O'Carroll; Eduardo M Sotomayor; J Montgomery; Ivan Borrello; L Hwang; S Fein; Drew M Pardoll; Hyam I Levitsky
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(3):1178-83.
1998: David J Morgan; Huub T C Kreuwel; S Fleck; Hyam I Levitsky; Drew M Pardoll; Linda A Sherman
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(2):643-51.
1998: A Nigam; R F Yacavone; M L Zahurak; C M Johns; Drew M Pardoll; Steven Piantadosi; Hyam I Levitsky; William G Nelson
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
International journal of oncology 1998;12(1):161-70.
1997: Hyam I Levitsky
Accessories for naked DNA vaccines.
Nature biotechnology 1997;15(7):619-20.
1997: Jonathan W Simons; Elizabeth M Jaffee; CE Weber; Hyam I Levitsky; William G Nelson; Michael A Carducci; A J Lazenby; LK Cohen; C C Finn; Shirley Clift; K M Hauda; Lisa A Beck; KM Leiferman; A H Owens; Steven Piantadosi; Glenn Dranoff; Richard C Mulligan; Drew M Pardoll; Fray F Marshall
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Cancer research 1997;57(8):1537-46.
1997: Hyam I Levitsky
Canarypox virus vectors for gene transfer in cancer immunotherapy.
Journal of the National Cancer Institute 1997;89(6):408-9.
1997: Hyam I Levitsky
The best cytokine for the job.
Nature medicine 1997;3(2):126.
1996: Hyam I Levitsky
Tumors derived from antigen presenting cells.
Seminars in immunology 1996;8(5):281-7.
1996: Hyam I Levitsky; J Montgomery; M Ahmadzadeh; K Staveley-O'Carroll; F Guarnieri; Dan Longo; L W Kwak
Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(10):3858-65.
1996: Elizabeth M Jaffee; M C Thomas; Alex Yee-Chen Huang; K M Hauda; Hyam I Levitsky; Drew M Pardoll
Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):176-83.
1996: Alex Yee-Chen Huang; Allen Bruce; Drew M Pardoll; Hyam I Levitsky
In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.
Immunity 1996;4(4):349-55.
1996: Alex Yee-Chen Huang; Allen Bruce; Drew M Pardoll; Hyam I Levitsky
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
The Journal of experimental medicine 1996;183(3):769-76.
1996: Eduardo M Sotomayor; Ivan Borrello; Hyam I Levitsky
Tolerance and cancer: a critical issue in tumor immunology.
Critical reviews in oncogenesis 1996;7(5-6):433-56.
1996: Shawn Robinson; P W Cho; Hyam I Levitsky; J L Olson; Ralph Hruban; M A Acker; P D Kessler
Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts.
Cell transplantation 1996;5(1):77-91.
1996: K Y Lin; F G Guarnieri; K Staveley-O'Carroll; Hyam I Levitsky; Thomas J August; Drew M Pardoll; Tzyy-choou Wu
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
Cancer research 1996;56(1):21-6.
1995: Tzyy-choou Wu; F G Guarnieri; K Staveley-O'Carroll; Raphael P Viscidi; Hyam I Levitsky; L Hedrick; Kathleen R Cho; Thomas J August; Drew M Pardoll
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11671-5.
1995: Tzyy-choou Wu; Alex Yee-Chen Huang; Elizabeth M Jaffee; Hyam I Levitsky; Drew M Pardoll
A reassessment of the role of B7-1 expression in tumor rejection.
The Journal of experimental medicine 1995;182(5):1415-21.
1995: Elizabeth M Jaffee; Audrey Lazenby; J Meurer; F Marshall; K M Hauda; C Counts; H Hurwitz; Jonathan W Simons; Hyam I Levitsky; Drew M Pardoll
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(1):1-9.
1995: A J Berns; Shirley Clift; LK Cohen; Ross C Donehower; Glenn Dranoff; K M Hauda; Elizabeth M Jaffee; Audrey Lazenby; Hyam I Levitsky; F F Marshall
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma.
Human gene therapy 1995;6(3):347-68.
1994: Alex Yee-Chen Huang; P Golumbek; M Ahmadzadeh; Elizabeth M Jaffee; Drew M Pardoll; Hyam I Levitsky
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
Science (New York, N.Y.) 1994;264(5161):961-5.
1994: Hyam I Levitsky; Audrey Lazenby; R J Hayashi; Drew M Pardoll
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
The Journal of experimental medicine 1994;179(4):1215-24.
1994: Alex Yee-Chen Huang; P Golumbek; M Ahmadzadeh; Elizabeth M Jaffee; Drew M Pardoll; Hyam I Levitsky
Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.
Ciba Foundation symposium 1994;187():229-40; discussion 240-4.
1993: P T Golumbek; R Azhari; Elizabeth M Jaffee; Hyam I Levitsky; Audrey Lazenby; K Leong; Drew M Pardoll
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
Cancer research 1993;53(24):5841-4.
1993: Glenn Dranoff; Elizabeth M Jaffee; Audrey Lazenby; P Golumbek; Hyam I Levitsky; K Brose; V Jackson; H Hamada; Drew M Pardoll; Richard C Mulligan
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(8):3539-43.
1993: P Golumbek; Hyam I Levitsky; L Jaffee; Drew M Pardoll
The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy.
Immunologic research 1993;12(2):183-92.
1992: P T Golumbek; Fayez M Hamzeh; Elizabeth M Jaffee; Hyam I Levitsky; Paul S Lietman; Drew M Pardoll
Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):224-30.
1992: Drew M Pardoll; P Golumbek; Hyam I Levitsky; L Jaffee
Molecular engineering of the antitumor immune response.
Bone marrow transplantation 1992;9 Suppl 1():182-6.
1991: P T Golumbek; Audrey Lazenby; Hyam I Levitsky; L M Jaffee; H Karasuyama; M Baker; Drew M Pardoll
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
Science (New York, N.Y.) 1991;254(5032):713-6.
1991: Hyam I Levitsky; P T Golumbek; Drew M Pardoll
The fate of CD4-8- T cell receptor-alpha beta+ thymocytes.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(4):1113-7.
1991: A Shuper; Hyam I Levitsky; David R Cornblath
Early invasive CNS aspergillosis. An easily missed diagnosis.
Neuroradiology 1991;33(2):183-5.
1990: Eric R Fearon; Drew M Pardoll; T Itaya; P Golumbek; Hyam I Levitsky; J W Simons; H Karasuyama; Bert Vogelstein; P Frost
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.
Cell 1990;60(3):397-403.
1981: S H Zigmond; Hyam I Levitsky; B J Kreel
Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis.
The Journal of cell biology 1981;89(3):585-92.